BIO-TECHNE Corp vs TKO Group Holdings Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while TKO Group Holdings Inc trades at $181.02 (market cap $13.06B). The key difference: BIO-TECHNE Corp and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays the higher dividend (1.77%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and TKO Group Holdings Inc for 30 Days on average.
| TECH | TKO | |
|---|---|---|
Market Cap | $11.37B | $13.06B |
Volume | 3,153,511 | 999,906 |
Sector | Health | Media |
52-Week High | $72.61 | $224.96 |
52-Week Low | $43.31 | $175.58 |
Typical Hold Time | 63 Days | 30 Days |
Enterprise Value | $11.40B | $17.42B |
Dividend Yield | 0.44% | 1.77% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
TKO trades at $178.64, down 1.24% on the day and near a 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings, missing Q2 2026 EPS estimates but beating Q1. Revenue growth is solid, with 2026 guidance raised to $5.3B, though high P/E of 62.68 signals premium valuation. A quarterly dividend of $0.79 was declared for September 2026.
Outlook is supported by strong analyst consensus (89% buy ratings) and a $227 price target, but risks include recent technical weakness, margin pressure, and competitive threats. The stock offers upside if media rights and live event execution drive earnings growth, yet volatility near lows warrants caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →